Does Affinity Health Plan Cover Ozempic?

What Is Affinity Health Plan and Which Members Does It Serve?

Affinity Health Plan is a New York-based managed care organization that administers Medicaid Managed Care, Child Health Plus, the Essential Plan, and select commercial products primarily in the New York City metropolitan area. The plan contracts with the New York State Department of Health, meaning its drug coverage policies must align with New York Medicaid formulary guidance while still leaving room for plan-level utilization management.

Knowing which Affinity product you hold matters before calling pharmacy benefits. Medicaid Managed Care members are governed by the New York State Medicaid preferred drug list, while Essential Plan members follow a slightly different benefit structure authorized under the ACA's Basic Health Program rules. Commercial plan members face a separate employer-negotiated formulary. Each of these benefit designs may place Ozempic on a different tier, apply different copay structures, or impose different prior authorization criteria.

Because Affinity operates under New York Medicaid managed care contracts, prescribers should consult both the state preferred drug list and Affinity's own formulary document, updated each January 1. The FDA-approved labeling for semaglutide (Ozempic) restricts the indication to adults with type 2 diabetes mellitus as an adjunct to diet and exercise, a point Affinity reviewers use when evaluating diabetes versus weight-loss requests.

How Affinity's Formulary Tiers Work for Ozempic

Formulary tier placement determines how much you pay at the pharmacy counter. Ozempic typically lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) across managed care plans in New York, which translates to copays ranging from roughly $45 to $100 per fill under commercial products, and nominal or zero cost-share under Medicaid for eligible members.

The Centers for Medicare and Medicaid Services (CMS) formulary guidance requires that plans covering a drug class include at least two chemically distinct drugs per class. GLP-1 receptor agonists as a class include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza), dulaglutide (Trulicity), and others. Affinity may prefer one GLP-1 agent over another, meaning a step-therapy requirement to try a preferred GLP-1 before approving Ozempic is legally permissible under New York managed care rules.

A 2022 analysis published in JAMA Internal Medicine found that among commercially insured patients prescribed GLP-1 agonists, 42% faced a prior authorization requirement and 18% experienced an initial denial. Those numbers are consistent with what Affinity members report anecdotally, and they underscore the value of submitting complete documentation on the first attempt.

Semaglutide's clinical evidence base is substantial. The SUSTAIN-6 trial (N=3,297) showed that once-weekly subcutaneous semaglutide 0.5 mg or 1 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 26% versus placebo (HR 0.74; 95% CI 0.58, 0.95; P<0.001 for non-inferiority) in patients with type 2 diabetes and high cardiovascular risk. PubMed PMID 27633186. That cardiovascular outcome data strengthens a prescriber's case when writing a prior authorization letter for a patient with T2DM and established atherosclerotic disease.

Prior Authorization: Step-by-Step for Affinity Members

Getting Ozempic covered through Affinity follows a predictable sequence. Each step requires specific documentation.

Step 1. Confirm the diagnosis on file. Affinity reviewers will verify that an ICD-10 code for type 2 diabetes mellitus (E11.x) appears in the member's claims history or in the PA request. A fasting plasma glucose of 126 mg/dL or greater on two separate occasions, or an HbA1c of 6.5% or greater, meets the ADA diagnostic threshold per the 2024 ADA Standards of Medical Care in Diabetes. Reviewers pull claims data, so a single office visit with the correct code attached matters.

Step 2. Document prior therapy. Most Affinity PA criteria for GLP-1 agents require that the patient has tried metformin at an adequate dose (typically 1,000, 2 to 000 mg/day for at least 90 days) unless a documented contraindication exists, such as an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m², or gastrointestinal intolerance. The FDA label for metformin notes that it is contraindicated when eGFR falls below 30. Providing lab values that justify skipping metformin can accelerate approval.

Step 3. Submit HbA1c values. Include a recent HbA1c result (within the last 6 months if possible) demonstrating inadequate glycemic control on current therapy. An HbA1c of 7.5% or greater on metformin monotherapy is a commonly accepted threshold for escalation to a second agent per ADA guidelines. 2024 ADA Standards, Section 9.

Step 4. Complete Affinity's PA request form. The prescriber or their staff submits through Affinity's online provider portal or by fax to the pharmacy benefit manager (PBM) contracted by Affinity. PA turnaround under New York Medicaid managed care rules is typically 3 business days for standard requests and 24 hours for urgent requests, per New York State Department of Health utilization management guidance.

Step 5. Respond to any additional information requests within 24 hours. Delayed responses are the single most common reason PAs lapse into administrative denial rather than clinical denial. Keep a copy of everything submitted.

The five-step framework above is designed for Affinity specifically. Other New York Medicaid managed care plans (Fidelis, MetroPlus, Healthfirst) use similar but not identical criteria, so do not assume the same form or threshold applies across plans.

What Happens If Affinity Denies the Prior Authorization?

A denial is not the end of the road. New York State law requires managed care organizations to provide a written explanation of denial within the same timeframe as the original determination. The denial letter will cite the specific clinical criteria that were not met.

Level 1 Internal Appeal. The prescriber or member submits a written appeal with additional documentation. An appeal that includes peer-reviewed literature, such as the cardiovascular outcome data from SUSTAIN-6 or the renal protection findings from the FLOW trial (N=3,533), which showed semaglutide 1 mg reduced the composite kidney endpoint by 24% versus placebo (HR 0.76; 95% CI 0.66, 0.88; P<0.001) in patients with type 2 diabetes and chronic kidney disease PubMed PMID 38785209, has a measurably stronger chance of reversal.

External Independent Review. If the internal appeal fails, New York State allows members to request an Independent Medical Review through the New York State Department of Financial Services. An external reviewer who is board-certified in endocrinology or internal medicine evaluates whether the denial met clinical standards. CMS data from 2023 indicate that approximately 40% of external drug-coverage reviews result in overturn of the original denial.

Expedited Appeal. When a patient's health would be seriously harmed by waiting, New York regulations allow an expedited internal appeal decided within 2 business days and an expedited external review decided within 72 hours. Prescribers must attest that delay poses a serious health risk.

A direct quotation from the 2024 ADA Standards captures the clinical rationale well: "For patients with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended as part of the glucose-lowering regimen independent of HbA1c." 2024 ADA Standards, Section 10. Including that language verbatim in an appeal letter ties the clinical request directly to a recognized national guideline.

Ozempic for Weight Loss Under Affinity: A Different Standard

Ozempic is FDA-approved only for type 2 diabetes. Wegovy (semaglutide 2.4 mg, also Novo Nordisk) is the FDA-approved formulation for chronic weight management, cleared under the FDA approval for Wegovy dated June 4, 2021. Affinity, like most managed care plans, will deny an Ozempic claim where the stated indication is weight loss without a concurrent T2DM diagnosis.

The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) PubMed PMID 33567185. That trial used Wegovy's dose, not Ozempic's. Prescribers who want coverage for weight management should submit a PA for Wegovy under the obesity diagnosis codes (E66.x), not for Ozempic under a weight-related diagnosis.

New York Medicaid has historically limited coverage of anti-obesity medications, though this is changing. The 2023 CMS Medicaid guidance on anti-obesity medications encouraged states to expand coverage for FDA-approved weight-loss drugs. New York has been evaluating this, meaning Affinity's Medicaid Managed Care product may update its Wegovy/Saxenda coverage criteria. Members should check the current formulary at plan renewal each year.

Cost Without Coverage: Manufacturer Savings and Alternatives

If Affinity denies coverage and appeals are exhausted, several cost-reduction options exist.

Novo Nordisk's Ozempic savings card is available to commercially insured patients (not Medicaid or Medicare) and can reduce the monthly out-of-pocket cost to as little as $25 for a 1-month or 3-month supply, subject to a monthly maximum benefit. The program details are available through Novo Nordisk's patient support line. Uninsured patients may qualify for the Novo Nordisk Patient Assistance Program, which provides free medication to those meeting income criteria.

Compounded semaglutide has been widely available during the FDA-declared shortage period, but the FDA's March 2024 and October 2024 shortage determinations affected whether compounding pharmacies could legally produce copies. As of early 2025, the FDA declared the Ozempic and Wegovy shortage resolved for certain presentations, which may limit access to compounded versions. Patients should verify current shortage status with their pharmacist and review FDA guidance on compounded semaglutide before pursuing that route.

Other GLP-1 agents that may carry lower cost or preferred tier status on Affinity's formulary include dulaglutide (Trulicity) and liraglutide (Victoza). A 2021 meta-analysis published in The Lancet Diabetes and Endocrinology that pooled data across eight GLP-1 cardiovascular outcomes trials found a class-level 14% reduction in major adverse cardiovascular events (RR 0.86; 95% CI 0.80, 0.93). That means switching to a covered GLP-1 agent may carry comparable cardiovascular protection if Ozempic specifically cannot be approved.

Documenting Medical Necessity: What Prescribers Should Include

A well-constructed prior authorization letter addresses every criterion the plan reviewer is trained to check. The letter should include the following specific elements.

The patient's most recent HbA1c (with the date of the draw), the current diabetes medication regimen with doses and duration, any documented adverse effects or contraindications to metformin, the patient's cardiovascular risk profile (including any established ASCVD, heart failure with reduced ejection fraction, or chronic kidney disease stage), and the prescriber's clinical rationale for choosing semaglutide over other available agents.

An endocrinologist's or cardiologist's note supporting the request carries weight. The American Association of Clinical Endocrinology 2023 Consensus Statement on Obesity states: "GLP-1 receptor agonists are now first-line adjunctive pharmacotherapy for patients with type 2 diabetes and obesity or overweight with weight-related comorbidities." Quoting that consensus position in the PA letter gives the reviewer a named guideline source to check rather than relying on the prescriber's opinion alone.

Lab values dated within 90 days carry more weight than older results. An eGFR drawn the same day as the PA submission can simultaneously document CKD (strengthening the FLOW-trial argument) and confirm that metformin dose adjustment or discontinuation was clinically appropriate.

How New York State Medicaid Rules Protect Affinity Members

New York State imposes specific protections on Medicaid Managed Care members that commercial plan members do not automatically receive. These protections matter when Ozempic is denied.

New York Social Services Law Section 364-j requires managed care organizations to cover medically necessary services. If a prescriber can document that Ozempic is medically necessary and that a formulary alternative has been tried and failed, the plan must cover the requested drug. "Medical necessity" under the New York Medicaid framework means care that is reasonably necessary to prevent, diagnose, correct, or treat a condition that causes suffering, threatens to cause or worsen disability, illness, or death, or results in illness or infirmity.

The New York State Office of the Medicaid Inspector General provides oversight of managed care coverage decisions. Filing a complaint with the OMIG or the New York State Department of Health Division of Managed Care can escalate a coverage dispute beyond the internal appeals track and sometimes produces faster resolution than waiting for an external review.

Members enrolled in the Essential Plan receive coverage through the Basic Health Program framework. Federal rules governing the Basic Health Program, administered by CMS, require that the benefit package be at least as generous as a silver-level qualified health plan. That floor does not guarantee Ozempic coverage, but it does mean the plan cannot offer materially worse drug coverage than a comparable marketplace silver plan without CMS approval.

Switching From Ozempic to a Covered GLP-1 Agent

When Ozempic coverage is definitively unavailable, switching to a Affinity-preferred GLP-1 agent is a practical clinical option. Dulaglutide 1.5 mg once weekly demonstrated non-inferior HbA1c reduction compared to semaglutide 0.5 mg in the AWARD-11 extension trial, though semaglutide 1 mg showed superior HbA1c reduction over dulaglutide 1.5 mg in a head-to-head analysis published in Diabetes Care. The difference in glycemic efficacy is clinically meaningful for patients with HbA1c above 9%, where the stronger agent may reduce hospitalization risk.

Liraglutide (Victoza) 1.2 mg or 1.8 mg once daily has demonstrated cardiovascular outcome benefit in the LEADER trial (N=9,340), reducing the three-point MACE composite by 13% versus placebo (HR 0.87; 95% CI 0.78, 0.97; P<0.001 for non-inferiority, P=0.01 for superiority) PubMed PMID 27295427. If Affinity's formulary lists Victoza on a preferred tier, a prescriber could pivot to that agent with strong cardiovascular outcome support.

The prescriber should document the formulary switch explicitly in the chart to preserve a trail showing that the coverage pathway, not inferior clinical judgment, drove the change. That documentation supports a future PA for Ozempic if the patient's plan changes, if Affinity updates its formulary, or if a generic semaglutide enters the market.

Tracking Formulary Changes: What to Check Each January

Affinity updates its formularies on January 1 each year, consistent with New York State Medicaid managed care contract cycles. Members who were denied in a prior year should resubmit a PA at the start of each new plan year, especially given the rapidly evolving GLP-1 formulary decisions across Medicaid plans nationally.

The CMS Medicaid Drug Rebate Program negotiates rebates with manufacturers that can shift the net cost of a drug to the plan substantially, sometimes moving a drug from non-preferred to preferred tier mid-year. Affinity is required to notify members of mid-year formulary changes at least 30 days in advance, per New York managed care regulations. Staying subscribed to Affinity's member newsletter or checking the online formulary search tool quarterly can catch favorable changes before the next prescription is due.

For the 2025 plan year, check whether Affinity's formulary now includes semaglutide under the Inflation Reduction Act drug negotiation provisions, which as of 2025 cover several high-cost medications. Semaglutide was not among the first ten drugs selected for price negotiation, but future rounds may include it, which could lower plan costs and reduce utilization management barriers.